Palladiem’s Ultragenyx Pharmaceutical RARE Stock Holding History

Palladiem’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,091	Closed	-$289K	–	66
2020 Q4	$289K	Buy	+2,091	New	+$248K	0.27%	44

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Palladiem's RARE Position: Q1 2021 in Review

Palladiem sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 2,091 shares — an estimated $289K sold.

Palladiem first reported a position in RARE in Q4 2020 and held it in 1 quarter. The position peaked at $289K in Q4 2020. 254 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

Palladiem reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
Palladiem sold 2,091 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $289K.
Palladiem first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 1 quarter.
Palladiem's Ultragenyx Pharmaceutical position peaked at $289K in Q4 2020.
254 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on Palladiem's 13F filing for Q1 2021, filed 12 May 2021.